Fig. 5.

TsAb3v1 and TsAb2v2 proliferation inhibition of NSCLC co-cultured cell lines. (A) RNA expression of cMet, HER1, HER3 and IGF1R in A549, H596, H322M and H441 cells measured by affymetrix analysis. (B) Percentage growth inhibition versus control of A549, H596, H322M, H441 cells grown individually and treated for 5 days with cMetHER3 BsAb, HER1/IGF1R BsAb, TsAb3v1 and TsAb2v2. Cell viability was evaluated in a Cell Titer Glo assay. (C) Percentage growth inhibition versus control of A549, H596, H322M, H441 cells cultivated in various combinations (shown as ± symbols below the graph) and treated for 5 days with cMetHER3 BsAb, HER1/IGF1R BsAb, TsAb3v1 and TsAb2v2. Cell viability was evaluated in a Cell Titer Glo assay. Statistical significance was evaluated versus the BsAb showing the strongest growth inhibitory effect; *P < 0.05; **P < 0.01; ***P < 0.001